By Nathan Allen
Sanofi said Monday that it has concluded the research-and-option phase of its rare-disease alliance with Alnylam Pharmaceuticals
Through the alliance, which was set up in 2014, the companies developed a treatment for patients with ATTR amyloidosis and are testing a molecule to treat hemophilia, Sanofi said.
In the new phase of the alliance Alnylam will proceed with another early-stage therapy for an undisclosed rare disease, taking it through to initial trials.
Sanofi said it will then be responsible for any further development of the therapy, paying royalties to Alnylam from global sales.
The two companies have amended their equity agreement, with France's Sanofi obtaining a release from its lock-up of trading in Alnylam's shares.
Write to Nathan Allen at email@example.com